Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2701 - 2725 of 3948 in total
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both...
Investigational
Matched Description: … the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
Matched Description: … developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 ... AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
Investigational
Matched Description: … under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Matched Description: … Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19
Matched Categories: … Experimental Unapproved Treatments for COVID-19
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.
Experimental
Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.
Investigational
Experimental
Investigational
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
MK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).
Investigational
Investigational
Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).
Investigational
Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have...
Investigational
Investigational
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum).
Investigational
ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
Investigational
Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class...
Investigational
Matched Iupac: … (1S,5R,13R,14S,17S)-14-(2,5,8,11,14,17-hexaoxanonadecan-19-yloxy)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo …
Investigational
Experimental
Matched Iupac: … (11S)-6-chloro-11-methyl-10-(3-methylbut-2-en-1-yl)-1,3,10-triazatricyclo[6.4.1.0^{4,13}]trideca-4(13 …
JTK-853 has been used in trials studying the treatment of Hepatitis C Virus Infection, Response to Therapy of.
Investigational
ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Investigational
Displaying drugs 2701 - 2725 of 3948 in total